University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma : TAGS RCT

Simple item page
dc.contributor.authorKing, Anthony J.
dc.contributor.authorFernie, Gordon
dc.contributor.authorHudson, Jemma
dc.contributor.authorKernohan, Ashleigh
dc.contributor.authorAzuara-Blanco, Augusto
dc.contributor.authorBurr, Jennifer
dc.contributor.authorHomer, Tara
dc.contributor.authorShabaninejad, Hosein
dc.contributor.authorSparrow, John M.
dc.contributor.authorGarway-Heath, David
dc.contributor.authorBarton, Keith
dc.contributor.authorNorrie, John
dc.contributor.authorMcDonald, Alison
dc.contributor.authorVale, Luke
dc.contributor.authorMaclennan, Graeme
dc.contributor.institutionUniversity of Aberdeen.Centre for Healthcare Randomised Trials (CHaRT)en
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2022-02-16T20:58:01Z
dc.date.available2022-02-16T20:58:01Z
dc.date.issued2021-11-01
dc.descriptionDeclared competing interests of authors: Anthony J King declares receiving honoraria payments from Thea Pharmaceutical (Keele, UK) and Allergan Pharmaceutical (Dublin, Ireland) for speaking at educational meetings. Augusto Azuara-Blanco declares membership of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Prioritisation Committee B (2020–present). Jennifer Burr declares membership of the NIHR HTA Clinical Evaluations and Trials Committee (2010–14). David Garway-Heath reports grants from NIHR for the HTA programme 12/35/38 during the conduct of the study; personal fees from Aerie Pharmaceuticals (Bedminster, NJ, USA), Allergan Pharmaceuticals, Bausch & Lomb (Rochester, NY, USA), Omikron (Beirut, Lebanon) and OptoVue (Fremont, CA, USA); personal fees and non-financial support from Carl Zeiss Meditec (Jena, Germany) and CenterVue (Padova, Italy); grants from Pfizer Inc. (New York, NY, USA) and Alcon Research Institute (Geneva, Switzerland); grants and personal fees from Santen Pharmaceutical (Osaka, Japan); and research equipment from Heidelberg Engineering (Heidelberg, Germany) and Topcon (Tokyo, Japan) outside the submitted work. David Garway-Heath also declared membership of the NIHR HTA Clinical Evaluations and Trials Committee (2014–17). John Norrie reports grants from University of Aberdeen and University of Edinburgh during the conduct of the study; and reports being a past and present member of the following: HTA Commissioning Sub-Board (EOI), NIHR Clinical Trials Unit Standing Advisory Committee, NIHR HTA and Efficacy and Mechanism Evaluation (EME) Editorial Board, Pre-Exposure Prophylaxis Impact Review Panel, EME Strategy Advisory Committee, EME Funding Committee Members, EME Funding Committee Sub-Group Remit and Comp Check, HTA General Committee, HTA Funding Committee Policy Group (formerly CSG) and the HTA Commissioning Committee. John Norrie also reports the HTA Post-funding Committee Teleconference (2016–19) and Covid Reviewing 2020. Luke Vale reports grants from NIHR HTA programme 12/35/38 during the conduct of the study. Luke Vale was also a member of the NIHR HTA Clinical Trials and Evaluation Panel from 2014 to 2018. John M Sparrow reports grants from NIHR HTA programme 12/35/38 during the conduct of the study, and was the previous chairperson of the National Institute for Health and Care Excellence Glaucoma Guideline Committee guideline published in 2017. Keith Barton reports personal fees from Allergan Pharmaceuticals, Alcon Pharmaceuticals, Laboratoires Thea (Clermont-Ferrand, France), EyeTechCare (Rillieux-la-Pape, France), Glaukos (San Clemente, CA, USA), Kowa Pharmaceuticals (Montgomery, AL, USA), Ivantis Inc. (Irvine, CA, USA), pH Pharma (South San Francisco, CA, USA), iStar Medical (Wavre, Belgium), Radiance Therapeutics (Tucson, AZ, USA) and EyeD Pharma (Liège, Belgium), grants from Allergan and Laboratoires Thea, stock from Vision Medical Events Ltd (London, UK), International Glaucoma Surgery Registry (London, UK) and MedEther Ophthalmology (London, UK), and a patent from Advanced Ophthalmic Implants outside the submitted work. This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 72. See the NIHR Journals Library website for further project information. The research reported in this issue of the journal was funded by the HTA programme as project number 12/35/38. The contractual start date was in January 2014. The draft report began editorial review in February 2020 and was accepted for publication in December 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.en
dc.description.statusPeer revieweden
dc.format.extent194
dc.format.extent3175992
dc.identifier213449248
dc.identifier09c8788d-38f3-4dce-88ab-40fe6d194609
dc.identifier85122486270
dc.identifier34854808
dc.identifier.citationKing, A J, Fernie, G, Hudson, J, Kernohan, A, Azuara-Blanco, A, Burr, J, Homer, T, Shabaninejad, H, Sparrow, J M, Garway-Heath, D, Barton, K, Norrie, J, McDonald, A, Vale, L & Maclennan, G 2021, 'Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma : TAGS RCT', Health Technology Assessment, vol. 25, no. 72, pp. i-158. https://doi.org/10.3310/hta25720en
dc.identifier.doi10.3310/hta25720
dc.identifier.iss72en
dc.identifier.issn1366-5278
dc.identifier.otherORCID: /0000-0002-1039-5646/work/108708677
dc.identifier.urihttps://hdl.handle.net/2164/18078
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85122486270&partnerID=8YFLogxKen
dc.identifier.vol25en
dc.language.isoeng
dc.relation.ispartofHealth Technology Assessmenten
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicine (General)en
dc.subjectHealth Policyen
dc.subject.lccR1en
dc.titlePrimary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma : TAGS RCTen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
King_et_al_Primary_trabeculectomy_HTA_vorpdf.pdf
Size:
3.03 MB
Format:
Adobe Portable Document Format
Download

Collections

All research